Antibacterial agents belonging to the fluoroquinolone group for systemic and inhalation use (ATOVAX®, OZERLIK®, POLIMIK®, TAIGERON®) – information on the risk of long-lasting serious adverse reactions and a reminder of restrictions on use

16.10.2023 Updated 04.12.2023 1854 views

Антибактеріальні засоби, що належать до групи фторхінолонів для системного та інгаляційного застосування (АТОВАКС®, ОЗЕРЛІК®, ПОЛІМІК®, ТАЙГЕРОН®) – інформація щодо ризику виникнення тривалих серйозних побічних реакцій та нагадування про обмеження застосуванняPDF · 194 КБ

Завантажити

Antibacterial agents belonging to the fluoroquinolone group for systemic and inhalation use (ATOVAX®, OZERLIK®, POLIMIK®, TAIGERON®) – information on the risk of long-lasting serious adverse reactions and a reminder of restrictions on use

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Antibacterial agents belonging to the fluoroquinolone group for systemic and inhalation use (ATOVAX®, OZERLIK®, POLIMIK®, TAIGERON®) – information on the risk of long-lasting serious adverse reactions and a reminder of restrictions on use

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration